What is ARVN's current stock price?

ARVN (Arvinas, Inc.) is currently trading at $9.09 with a market cap of $586.5M.

What sector is Arvinas, Inc. in?

Arvinas, Inc. (ARVN) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ARVN a good stock to buy?

Analysts have a Hold consensus on ARVN with a price target of $14.75. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ARVN Arvinas, Inc.

Healthcare

$9.09-0.11%ClosedMarket Cap: $586.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.50

P/S

6.56

EV/EBITDA

-2.19

DCF Value

$-123.93

FCF Yield

-43.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

97.4%

Operating Margin

-279.3%

Net Margin

-247.5%

ROE

-44.4%

ROA

-34.2%

ROIC

-46.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$15.6M	$-57.6M	$—
Q4 null	$9.5M	$-67.4M	$—
FY null	$262.6M	$-80.8M	$—
Q3 null	$41.9M	$-35.1M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$14.75

Target (Median)

$14.50

Target Range

$10.00 - $20.00

2 Strong Buy8 Buy8 Hold1 Sell0 Strong Sell

BTIGBuy

2026-05-13

BarclaysOverweight

2026-05-13

CitigroupBuy

2026-05-04

CitigroupBuy

2026-03-19

BTIGBuy

2026-03-19

Trading Activity

Insider Trades

View All

Teel Randydirector, officer: President and CEO

SellFri May 22

Teel Randydirector, officer: President and CEO

SellWed May 13

Saik Andrewofficer: Chief Financial Officer

SellWed May 13

Loomis David Kofficer: VP, Chief Accounting Officer

SellWed May 13

Cacace Angela Mofficer: Chief Scientific Officer

SellWed May 13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.80

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Peers

DNA